Related Experiment Video

Updated: Jun 18, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Hepatocyte growth factor--a new marker for prognosis in acute coronary syndrome

Anna Konopka1, Jadwiga Janas, Walerian Piotrowski

  • 1Institute of Cardiology CCU, ul. Alpejska 42, Warsaw, Poland. akonopka@ptkardio.pl

Growth Factors (Chur, Switzerland)
|November 27, 2009
PubMed

Insights

Hepatocyte growth factor (HGF) shows promise as an early marker for myocardial necrosis in acute coronary syndrome (ACS). Higher HGF levels correlate with adverse outcomes, indicating its prognostic value.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Molecular Medicine

Background:

  • Acute coronary syndrome (ACS) necessitates reliable markers for myocardial necrosis.
  • Early identification of myocardial damage is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To evaluate hepatocyte growth factor (HGF) as a novel biomarker for myocardial necrosis.
  • To assess the prognostic significance of HGF in patients with ACS.

Main Methods:

  • Plasma human HGF (hHGF) concentrations were measured in 104 ACS patients upon admission and 24 hours later.
  • Correlation analysis was performed between hHGF levels and established cardiac biomarkers (NT-proBNP, troponin I).
  • A three-month follow-up assessed a composite primary endpoint.

Main Results:

  • Maximal hHGF levels were observed at hospital admission, decreasing significantly by 24 hours (p < 0.0001).
  • Elevated hHGF levels were noted in ST-segment elevation myocardial infarction (STEMI) compared to non-STEMI.
  • Patients reaching the composite endpoint had significantly higher hHGF levels (4211 pg/ml) than event-free patients (1013 pg/ml, p < 0.01).

Conclusions:

  • HGF serves as a very early and effective marker of myocardial necrosis.
  • HGF demonstrates sensitivity as both a short- and long-term prognostic factor in ACS patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...